Name | Number of supported studies | Average coverage | |
---|---|---|---|
GABAergic neuron | 3 studies | 29% ± 9% | |
glutamatergic neuron | 3 studies | 38% ± 7% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 26% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
stomach | 100% | 246.16 | 358 / 359 | 88% | 2.17 | 253 / 286 |
intestine | 100% | 294.81 | 966 / 966 | 87% | 2.05 | 456 / 527 |
esophagus | 100% | 230.70 | 1440 / 1445 | 84% | 2.01 | 154 / 183 |
breast | 100% | 295.62 | 459 / 459 | 83% | 2.18 | 923 / 1118 |
lung | 100% | 268.11 | 577 / 578 | 81% | 1.52 | 936 / 1155 |
skin | 100% | 353.17 | 1809 / 1809 | 76% | 1.80 | 360 / 472 |
pancreas | 100% | 201.90 | 328 / 328 | 74% | 1.29 | 132 / 178 |
prostate | 100% | 254.01 | 245 / 245 | 72% | 1.60 | 363 / 502 |
kidney | 100% | 183.30 | 89 / 89 | 67% | 1.36 | 608 / 901 |
bladder | 100% | 256.19 | 21 / 21 | 63% | 1.25 | 319 / 504 |
thymus | 100% | 294.72 | 653 / 653 | 59% | 1.02 | 355 / 605 |
uterus | 100% | 309.79 | 170 / 170 | 58% | 1.04 | 266 / 459 |
brain | 95% | 126.27 | 2518 / 2642 | 62% | 1.07 | 435 / 705 |
adrenal gland | 100% | 319.94 | 257 / 258 | 48% | 0.87 | 111 / 230 |
ovary | 100% | 285.87 | 180 / 180 | 47% | 0.72 | 201 / 430 |
liver | 100% | 154.64 | 225 / 226 | 23% | 0.34 | 94 / 406 |
adipose | 100% | 289.20 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 271.31 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 257.43 | 1333 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 179.54 | 801 / 803 | 0% | 0 | 0 / 0 |
heart | 96% | 191.97 | 826 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 65% | 183.56 | 606 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 51% | 0.82 | 23 / 45 |
lymph node | 0% | 0 | 0 / 0 | 38% | 0.66 | 11 / 29 |
eye | 0% | 0 | 0 / 0 | 24% | 0.35 | 19 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006490 | Biological process | oligosaccharide-lipid intermediate biosynthetic process |
GO_0006487 | Biological process | protein N-linked glycosylation |
GO_0006488 | Biological process | dolichol-linked oligosaccharide biosynthetic process |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0004377 | Molecular function | GDP-Man:Man3GlcNAc2-PP-Dol alpha-1,2-mannosyltransferase activity |
GO_0000026 | Molecular function | alpha-1,2-mannosyltransferase activity |
Gene name | ALG11 |
Protein name | GDP-Man:Man(3)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase (EC 2.4.1.131) (Asparagine-linked glycosylation protein 11 homolog) (Glycolipid 2-alpha-mannosyltransferase) GDP-Man:Man(3)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase (EC 2.4.1.131) ALG11 alpha-1,2-mannosyltransferase |
Synonyms | GT8 |
Description | FUNCTION: Mannosyltransferase involved in the last steps of the synthesis of Man5GlcNAc(2)-PP-dolichol core oligosaccharide on the cytoplasmic face of the endoplasmic reticulum. Catalyzes the addition of the 4th and 5th mannose residues to the dolichol-linked oligosaccharide chain. . FUNCTION: Required for N-linked oligosaccharide assembly. . FUNCTION: Required for N-linked oligosaccharide assembly. . |
Accessions | A0A3B3IS90 ENST00000679544.1 A0A7P0T8Y4 ENST00000616513.1 A0A7P0T8B1 A0A7P0T9G5 ENST00000681047.1 ENST00000523764.1 ENST00000521508.2 A0A3B3ISP7 A0A7P0Z4B5 Q2TAA5 ENST00000650049.2 ENST00000681145.1 ENST00000679359.1 ENST00000681053.1 A0A3B3ISU2 ENST00000649708.2 ENST00000649340.2 Q5TAP0 A0A087WYL8 |